LabCorp Strengthens Leadership Position in Precision Medicine with Expansion of Therapeutic Drug Monitoring Portfolio
Summary
BURLINGTON, N.C.--( BUSINESS WIRE )--LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced a new assay in its therapeutic drug monitoring (TDM) DoseASSURE® portfolio. LabCorp’s DoseASSURE® portfolio helps address these challenges by providing quantitative, patient-specific measurement which can guide patient therapy. “Biologic drugs can be life-changing, but individual patient response to biologics can vary greatly,” said David P. King, LabCorp’s chairman and CEO. “LabCorp’s DoseASSURE portfolio helps to deliver on the promise of precision medicine by enabling more effective and more individualized treatment plans that can improve clinical outcomes at reduced costs.” Studies demonstrate the use of TDM can improve efficacy and prolong successful response to biologic treatment.